QuatRx gains $125M licensing pact

QuatRx has scored a $125 million licensing deal with Shionogi. The Japanese company will pay $25 million of that upfront for the worldwide marketing rights to ospemifene for the treatment of post-menopausal vulvovaginal atrophy. And NDA is planned later this year. QuatRx release

Suggested Articles

Just a few months after a series B-plus worth $75 million, U.S.-China biotech Harbour BioMed has nabbed a major $102.8 million series C.

A who’s who of Big Pharmas, including Pfizer, Johnson & Johnson and Merck, have banded together to bolster the development of new antibiotics.

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.